ZT Bloomgarden - Diabetes Care, 2007 - Am Diabetes Assoc Perspectives on the News commentaries are now part of a new, free monthly CME
activity. The Mount Sinai School of Medicine, New York, New York, is designating
this activity for 2.0 AMA PRA Category 1 credits. If you wish to ... Cited by 18 - Related articles - BL Direct - All 7 versions
GI Uwaifo, RE Ratner - The American Journal of Cardiology, 2007 - Elsevier Cardiovascular disease (CVD) burden remains the predominant cause of mortality
and morbidity in the United States and in most of the developed world. The
ongoing twin epidemics of obesity and type 2 diabetes mellitus provide a ... Cited by 9 - Related articles - All 32 versions
[CITATION] PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or …
RI Misbin - Diabetes Care, 2007 - Am Diabetes Assoc The year 1995 marked a sea change in availablilty of drugs to treat type 2
diabetes. The approval of metformin, a biguanide, was followed by the approval
of acarbose, a galactosidase inhibitor that, like metformin, had been ... Cited by 4 - Related articles - All 4 versions
- ►oxfordjournals.org DJ Betteridge, RA DeFronzo, RJ Chilton - European Heart Journal, 2008 - Eur Soc Cardiology The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive)
remains the only completed cardiovascular (CV) outcomes study with a
thiazolidinedione. It has provided valuable information on the impact of ... Cited by 12 - Related articles - BL Direct - All 10 versions
[CITATION] Effects of Pioglitazone in patients with type 2 diabetes with or without previous stroke. …
SS Lund, L Tarnow, CD Stehouwer, CG … - Diabetes, Obesity and Metabolism, 2007 - interscience.wiley.com Aim: Metformin is the 'drug-of-first-choice' in obese patients with type 2
diabetes mellitus (T2DM) due to its antihyperglycaemic and cardiovascular
protective potentials. In non-obese patients with T2DM, insulin ... Cited by 11 - Related articles - All 4 versions
[CITATION] Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive …
DM Riche, R Valderrama, NN Henyan - Diabetes Care, 2007 - Am Diabetes Assoc OBJECTIVE—Thiazolidinediones (TZDs) (rosiglitazone and pioglitazone) are a
class of antidiabetes agents that have a high affinity for peroxisome
proliferator–activated receptor-γ. TZDs initiate a multitude of ... Cited by 26 - Related articles - All 6 versions
- ►eje-online.org SS Lund, L Tarnow, CDA Stehouwer, CG … - European Journal of Endocrinology, 2008 - EFES Results: Levels of tumour necrosis factor- , plasminogen activator inhibitor-1
antigen, tissue-type plasminogen activator antigen, von Willebrand factor,
soluble intercellular adhesion molecule-1 and soluble E-selectin were ... Cited by 12 - Related articles - BL Direct - All 6 versions
